Can targeted therapies be applied to patients with Alzheimer’s?

Tara Mastren, center, is leading research into developing targeted alpha-particle therapies for patients with Alzheimer’s. The University of Utah professor of civil & environmental engineering is pictured here in her lab with graduate students Connor Holiski, left, and Aidan Bender.
Credit: Dan Hixson, University of Utah

University of Utah researchers develop potential alpha-particle treatments that target the plaques on the brain that lead to dementia.

Alzheimer’s disease, a debilitating brain disorder with limited treatment options, has long challenged researchers. Specifically, researchers have struggled with slowing the buildup of amyloid beta plaques, harmful clumps of proteins that exacerbate the disease by damaging brain cells and causing memory loss.

Led by the John and Marcia Price College of Engineering, University of Utah researchers have developed a groundbreaking approach to tackle these plaques and possibly slow this devastating neurodegenerative disease.

Inspired by targeted cancer treatment methods, their technique utilizes a form radiation known as alpha particles to break down chemical bonds in amyloid beta plaques. Targeted Alpha Therapy (TAT) delivers these particles directly to the harmful plaques on the brain while aiming to minimize damage to healthy tissues.

Aidan Bender, a former graduate student in the college’s Utah Nuclear Engineering Program, spearheaded this pioneering research published July 25 in the Journal of Nuclear Medicine, the premier journal in the field. Co-authors included researchers from the U departments of Radiology and Chemistry.

“Aidan excelled in research and developed many skills and techniques needed to tackle this study,” said the study’s senior author Tara Mastren, an assistant professor of civil and environmental engineering. “The research from his publication is the first step in determining if this treatment method is feasible and has allowed us to move into testing in vivo models.”

New hope for Alzheimer’s patients

Alzheimer’s disease is a leading cause of dementia in the United States, resulting in more than $200 billion in medical expense a year. The number of cases is expected to double by 2050, but the disorder’s impact could be lessened if treatments can be developed to slow its progress.

The Utah researchers turned to theoretical nuclear medicine in search of answers.

Under Mastren’s supervision, Bender’s team started by developing a chemical compound, called BiBPy, that can latch onto to the harmful amyloid beta plaques.

They attached a small amount of a radioactive isotope, bismuth-213, enabling the compound to emit alpha particles. This new compound, [213Bi]-BiBPy, was applied to the brain tissue of mice that were genetically modified to develop amyloid plaques similar to those in Alzheimer’s patients.

The compound, when combined with bismuth-213, demonstrated properties that made it effective at binding to the mice’s amyloid plaques.

Measured using two types of tests for the presence of amyloid beta, the treated brain tissues showed a significant reduction in amyloid beta concentration. These results suggest that the compound may be effectively applied as a potential TAT treatment for Alzheimer’s and other neurodegenerative diseases, paving the way for further tests in live animals and eventually in humans.

Since earning his doctorate, Bender has joined the Center for Quantitative Cancer Imaging at Huntsman Cancer Institute where he works on radiopharmaceutical development for cancer imaging and therapy. By harnessing cyclotron-produced therapeutic radionuclides, auger electron therapy, and PET radiometals, his research may lead to new tools for detecting, diagnosing and treating cancer.

This research was supported the U’s 1U4U initiative, which aims to bring together researchers from health sciences and the U’s main campus to broaden the societal impact of the university’s research. Engineering faculty worked in collaboration with Andrew Roberts, an associate professor of chemistry, and his graduate student Emily Kirkeby, and Satoshi Minoshima and Donna Cross of the Department of Radiology.

The study, titled “Development of a Bismuth-213 Labeled Pyridyl Benzofuran for Targeted α-Therapy of Amyloid-β Aggregates,” was published July 25 online by the Journal of Nuclear Medicine. Funding came from the National Cancer Institute, University of Utah and the NRC Graduate Research Fellowship program.

Journal: Journal of Nuclear Medicine
DOI: 10.2967/jnumed.124.267482
Method of Research: Observational study
Subject of Research: Not applicable
Article Title: Development of a 213Bi-Labeled Pyridyl Benzofuran for Targeted α-Therapy of Amyloid-β Aggregates
Article Publication Date: 25-Jul-2024
COI Statement: The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Research was partially funded by the NRC Graduate Research Fellowship under award 31310019M0042. No other potential conflict of interest relevant to this article was reported.

Media Contact

Brian Maffly
University of Utah
brian.maffly@utah.edu
Cell: 801-573-2382

Media Contact

Brian Maffly
University of Utah

All latest news from the category: Medical Engineering

The development of medical equipment, products and technical procedures is characterized by high research and development costs in a variety of fields related to the study of human medicine.

innovations-report provides informative and stimulating reports and articles on topics ranging from imaging processes, cell and tissue techniques, optical techniques, implants, orthopedic aids, clinical and medical office equipment, dialysis systems and x-ray/radiation monitoring devices to endoscopy, ultrasound, surgical techniques, and dental materials.

Back to home

Comments (0)

Write a comment

Newest articles

The last missing piece of silicon photonics

International research team presents first electrically pumped continuous-wave semiconductor laser suitable for seamless silicon integration. Scientists from Forschungszentrum Jülich, FZJ, the University of Stuttgart, and the Leibniz Institute for High…

Space-time crystals, an important step toward new optical materials

KIT scientists design tailored materials for optical information processing. Photonic space-time crystals are materials that could increase the performance and efficiency of wireless communication or laser technologies. They feature a…

Quasiparticle loss in extreme quantum materials

A new study by Rice University physicist Qimiao Si unravels the enigmatic behaviors of quantum critical metals — materials that defy conventional physics at low temperatures. Published in Nature Physics…